Ultimovacs

📍 Oslo, Norway🗓 Founded 2011👥 32 employees💰 Last funded Jan 2015
Biotechnology🌐 ultimovacs.com
Website LinkedIn
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe, Australia, and the USA; Five Phase II trials enrolling more than 650 patients at 100 clinics in 15 countries, in melanoma, mesothelioma, head & neck cancer, ovarian cancer, and non-small cell lung cancer. Ultimovacs was established in 2011. The company and its proprietary technology is based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is privately held, mainly by Norwegian private investors/family offices. Ultimovacs is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway, and also has an office in Uppsala, Sweden. Ultimovacs is an active member of Oslo Cancer Cluster.
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2011
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Norway
2
Frequently asked questions
Who invested in Ultimovacs?
Ultimovacs has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Ultimovacs last raise funding?
The most recent investment in Ultimovacs recorded on gritt.io was in January 2015.
When was Ultimovacs founded?
Ultimovacs was founded in 2011.
What industry is Ultimovacs in?
Ultimovacs operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Ultimovacs based?
Ultimovacs is headquartered in Oslo, Norway.